[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depressive-symptoms-mild-to-moderate-in-severity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depressive-symptoms-mild-to-moderate-in-severity":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,86,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100614811","depressive-symptoms-cognitive-impairment-and-outcomes-in-hospitalized-chronic-heart-failure-patients-100614811",false,"NCT07284446","Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients","Prevalence of Depressive Symptoms and Cognitive Impairment and Their Association With Worse Outcomes in a Cohort of Hospitalized Patients With Chronic Heart Failure","DSCI-CHF","Inclusion Criteria:\n\n* patient hospitalized primarily for CHF exacerbation;\n* clinically stable, able to provide informed consent;\n* do not have severe cognitive impairment that would preclude valid questionnaire administration.\n\nExclusion Criteria:\n\n* hospitalization for acute heart failure;\n* total length of hospital stay \\\u003C96 hours;\n* absence of transthoracic echocardiography (TTE) within the last 12 months and no TTE planned;\n* severe visual impairment preventing completion of the visual part of the Montreal Cognitive Assessment;\n* refusal to participate.","ALL","18 Years","85 Years",{"count":21,"type":22},300,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to learn about the prevalence of depressive symptoms and cognitive impairment and their association with worse outcomes in a cohort of hospitalized patients between the ages of 18 ang 85 years with chronic heart failure. The main question it aims to answer is:\n\n• Does the presence of depressive symptoms and cognitive impairment lead to worse outcomes in a cohort of hospitalized patients with chronic heart failure? Participants who are hospitalized due to exacerbation of chronic heart failure will answer survey questions to assess their cognitive function and depressive symptoms.",[27,28,29],"Congestive Heart Failure Chronic","Cognitive Impairment, Mild","Depressive Symptoms Mild to Moderate in Severity",[31,32,33,34,35],"Congestive Heart Failure","Mild Cognitive Impairment","Long-term Outcomes","Mild Depressive Symptoms","Rehospitalizations","RECRUITING","2025-12-02",{"date":39,"type":40},"2025-12-16","ACTUAL",{"date":37,"type":40},{"date":43,"type":22},"2028-12-02",{"name":45,"class":46},"Lithuanian University of Health Sciences","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":24,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":5},"100546094","adolescent-interpersonal-counseling-in-primary-care-100546094","NCT06390462","Adolescent Interpersonal Counseling in Primary Care","Adolescent Depression Treatment Pathways in Primary Care - a Longitudinal Cohort Study Describing Naturalistic Flow of Treatment and Evaluating Effectiveness and Cost-effectiveness of Interpersonal Counseling Compared to Treatment as Usual","Inclusion Criteria:\n\n* we will include all adolescents attending grades 7 to 9 in selected schools with on informed consent\n\nExclusion Criteria:\n\n* psychiatric care within the past 12 months or receiving a psychosocial intervention (psychotherapy, IPC-A, any other therapy of support) during the 12 months before baseline,\n* an inability to reliably understand the Finnish, Plain Finnish, Swedish, or English versions of the survey, or\n* an adolescents' or caretakers' report of a need for exclusion, such as another medical condition - including a mental disorder - requiring acute current treatment or support.",true,"13 Years","16 Years",{"count":59,"type":22},9000,"10 Years","The demand for prevention and treatment of adolescent depression has rapidly increased over years. A national project to improve treatment of adolescent depression in primary care has taken place in Finland starting 2020.\n\nThe goal of this prospective observational cohort study is to describe pathways to mental health services in adolescents with depressive symptoms. The main questions it aims to answer are:\n\n* Do young people reporting depressive symptoms have equal access to treatment?\n* How is it best to recognize those adolescents who will benefit from IPC-A?\n\nAdolescents who participate in the study will\n\n* complete a survey on protective and risk factors of depression three times over 6 months\n* report possible depressive symptoms every two weeks over 6 months\n* report whether they needed and received help, motivation for treatment, and benefits and harms from treatment\n\nWe will also collect\n\n* information from one of caretakers with two surveys within 6 month- intervals on their view on adolescent's need for support, strengths and risks, and benefits and harms from treatment where applicable\n* where applicable, from the professional who provided support after the intervention on their training and competence, as well as content of and response to treatment\n* register data to estimate overall provision and cost of social welfare and health care services one year preceding the study and over 2 to 10 years after the observation period\n\nResearchers will compare an intervention that is new in Finland, adolescent interpersonal counseling (IPC-A), to other treatments of depression, to see if it is equal to or better than other treatments of depression.",[29,63],"Major Depressive Disorder",[65,66,67,68,69,70,71,72,73,74,75],"adolescent","depression","prospective","cohort study","interpersonal counseling","prevention","therapy","effectiveness","cost-effectiveness","predictor","economic evaluation","2025-08-18",{"date":78,"type":40},"2025-08-19",{"date":80,"type":40},"2024-03-25",{"date":82,"type":22},"2039-12",{"name":84,"class":85},"Finnish Institute for Health and Welfare","OTHER_GOV",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100585658","a-pilot-study-of-synbiotics-in-adults-with-depressive-symptoms-100585658","NCT06905223","A Pilot Study of Synbiotics in Adults With Depressive Symptoms","A Pilot Study on the Efficacy of a Synbiotic Formula (MQU10) in Improving Mood and Well-being in Adults With Mild to Moderate Depressive Symptoms","Inclusion Criteria:\n\n* Individuals aged 18 or above\n* Patient Health Questionnaire-9 (PHQ-9) score between 5 to 14\n* Literate and can complete the self-report questionnaires\n* Able to understand the consent and sign the informed consent form\n\nExclusion Criteria:\n\n* Current diagnosis of substance abuse or dependence;\n* A current or past history of bipolar disorder, manic or hypomanic episodes, schizophrenia, personality disorder, posttraumatic stress disorder (PTSD), intellectual disability, neurodegenerative disorders (e. g, Parkinson's disease) or organic mental disorder\n* Requiring immediate psychiatric care (e. g, imminently suicidal subjects) or have attempted suicide in the past 3 months\n* Use of antipsychotics, antidepressants or sedatives, unless on a stable dose in the last 4 weeks\n* History of severe organ failure, renal failure on dialysis, HIV infection\n* Active malignancy within 5 years\n* History of major surgery on the gastrointestinal tract, except cholecystectomy and appendectomy in the past 5 years\n* Night shift work\n* History of antibiotic use within 4 weeks\n* History of allergy to probiotics or lactose leading to a severe allergic reaction\n* Known pregnancy or lactating",{"count":94,"type":22},30,"INTERVENTIONAL",[97],"NA","This study aims to explore the efficacy and safety of a synbiotic formula (MQU10) in improving mood and well-being in adults with mild to moderate depressive symptoms.",[29],[101,102,103],"Depressive symptoms","Synbiotics","Adult Mood","2025-06-04",{"date":106,"type":40},"2025-06-08",{"date":108,"type":40},"2025-04-03",{"date":110,"type":22},"2027-09-26",{"name":112,"class":113},"GenieBiome Limited","INDUSTRY",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":95,"phases":125,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":47},"100567236","early-phase-1-effects-of-intranasal-ketamine-on-depression-and-anxiety-in-palliative-care-cancer-patients-100567236","NCT06665568","Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients","Keta-Care - Antidepressant and Anxiolytic Effects of Intranasal Ketamine Self-administration in Palliative Care Cancer Patients: an Open-label Feasibility Study","Keta-Care","Inclusion Criteria (patients):\n\n* Informed Consent as documented by signature;\n* HADS total score of 6 or greater;\n* Age 18 years or older;\n* Progressive cancer diagnosis (estimated life expectancy 24 months or more)\n* Able to attend study visits;\n* Ability to speak and understand German;\n\nExclusion Criteria (patients):\n\n* Clinician assessed cognitive impairment;\n* Clinician assessed alcohol or drug abuse;\n* Pregnancy or breast-feeding;\n* Severe hypertension (greater than 200\u002F120 mmHg);\n* Anamnestic mood disorder (major depressive disorder, treatment resistant depression, etc.);\n* Suicidality (C-SSRS total score of \"low\" or less);\n* Weight less than 39 kg, greater than 170 kg;\n* Angina pectoris or myocardial infarction in the last 6 months;\n* Lifetime abuse or dependence on ketamine or phencyclidine;\n* Substance abuse or dependence in the 6 months before screen;\n* Nasal obstructions or history of nasal surgery.\n* Serious health risk caused by increased blood pressure or intracranial pressure:\n* Known aneurysmal vascular disease (including intracranial, thoracic or abdominal aortic or peripheral arterial vessels);\n* Known history of intracerebral hemorrhage;\n* Recent (within 6 weeks) cardiovascular event including myocardial infarction (MI).\n\nInclusion criteria (caregivers):\n\n* Informed Consent as documented by signature;\n* Age 18 years or older;\n* Able to attend study visits;\n* Ability to speak and understand German.\n\nExclusion criteria (caregivers):\n\n\\- None.",{"count":124,"type":22},100,[126],"EARLY_PHASE1","With progression of cancer, patients and their caregivers experience challenging emotional distress, which can make them feel depressed and very anxious.\n\nPatients with advanced cancer often do not have long to live. However, most antidepressants take a long time to act and cause unwanted side effects. There is hence a need for a fast acting antidepressant with fewer unwanted side effects.\n\nKetamine is an effective and fast acting antidepressant originating from pain treatment, which has few unwanted side effects. It can be taken by a patient as a nasal spray when it is needed.\n\nThe idea of treating depression and anxiety in cancer patients in palliative care with ketamine nasal spray is new. How effective ketamine will be at reducing depression and anxiety in patients is unknown . It is also unknown whether this kind of treatment will be safe and practical for palliative care patients.\n\nThis study aims to answer these questions. Patients will be treated with a low dose (5 mg) of ketamine nasal spray and then measure its effectiveness, practicality and safety. Questionnaires will be used to measure these outcomes.\n\nIf treating depression and anxiety with ketamine nasal spray proves to be effective, practical and safe, then it could help to improve the quality of life for palliative care patients and reduce the burden of their caregivers.",[29,129,130,131,132],"Anxiety","Quality of Life (QOL)","Caregiver Burden","Sleep Quality",[134,135,136,137,129,138,139,140],"Ketamine","Caregiver burden","Open-label","feasibility","Depression","Palliative Care","Intranasal","NOT_YET_RECRUITING","2025-04-28",{"date":144,"type":40},"2025-05-01",{"date":146,"type":22},"2025-04",{"date":148,"type":22},"2026-12",{"name":150,"class":46},"University of Zurich"]